Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.00005 par value
-
Shares outstanding
-
7.18M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
207K
-
Shares change
-
+49.1K
-
Total reported value, excl. options
-
$469K
-
Value change
-
+$407K
-
Number of buys
-
22
-
Number of sells
-
-4
-
Price
-
$2.27
Significant Holders of BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI) as of Q4 2024
30 filings reported holding BCLI - BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value as of Q4 2024.
BRAINSTORM CELL THERAPEUTICS INC. - Common Stock, $0.00005 par value (BCLI) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 207K shares
of 7.18M outstanding shares and own 2.88% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (78.4K shares), GEODE CAPITAL MANAGEMENT, LLC (52.5K shares), BlackRock, Inc. (25.2K shares), HRT FINANCIAL LP (20K shares), TWO SIGMA SECURITIES, LLC (11.3K shares), Ikarian Capital, LLC (6.02K shares), MORGAN STANLEY (4.32K shares), UBS Group AG (3.47K shares), CITIGROUP INC (1.97K shares), and OSAIC HOLDINGS, INC. (1.92K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.